课题基金 / 基金详情

MOOD EFFECT OF TESTOSTERONE VS FLUOXETINE IN HIV ILLNESS

MOOD EFFECT OF TESTOSTERONE VS FLUOXETINE IN HIV ILLNESS
睾酮与氟西汀对艾滋病毒疾病的情绪影响
批准号:
6073821
负责人:
JUDITH G. RABKIN
金额:
$7.04万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-09-30 至 2001-04-30

项目摘要

项目成果

JUDITH G. RABKIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Applicant's Abstract): In this competitive continuation application, the primary goal is to evaluate the antidepressant effects of testosterone compared to fluoxetine in a double-blind randomized placebo controlled clinical trial for HIV-positive patients with major depression as well as clinical symptoms of hypogonadism. In the first 2 years of the ongoing testosterone grant, the investigators treated HIV-positive men with clinical symptoms of hypogonadism in a 12-week open trial followed by a 6-week double-blind placebo controlled discontinuation trial with improved libido as the major outcome criterion. In the discontinuation phase, 79 percent (26/33) randomized to testosterone maintained response, compared to 15 percent (5/34) for placebo. Twenty-seven men in this sample had major depression. Of these, 21 (78 percent) had significantly improved mood after 8 weeks of open treatment. In the ongoing NIMH-supported placebo controlled trial of fluoxetine, 36 patients with major depression have been treated with fluoxetine, and 22 with placebo in a double-blind randomized trial. Response rates to fluoxetine and placebo respectively have been 75 percent and 45 percent. The results, taken together, suggest the value of a study designed to directly compare antidepressant effects of testosterone, fluoxetine, and placebo. The design will be an 8-week double blind 3-arm study of testosterone injections (and placebo capsules), fluoxetine (and placebo injections), and placebo (placebo injections and placebo capsules). The investigators propose a 2:1:1 randomization with 140 patients (70:35:35) completing the 8-week trial. The testosterone arm is the largest since they seek to determine whether an antidepressant effect is secondary to or independent of androgenic (increased libido) or anabolic (increased weight and/or muscle mass) effects. After this trial, treatment will be continued for another 4 months to assess longer-term patient acceptance, side effects, and safety, using HIV RNA viral load to gauge immune effects. The intent is to identify a practical, inexpensive, useful treatment for community settings.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Return to Work RCT: Counseling after Fatigue Treatment in HIV/AIDS
Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS
Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS
Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS
海外基金